AAVCAGsCD59, prednisone clinical trials

A long-term extension study of JNJ-81201887 (AAVCAGsCD59) parent studies in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

This study looks at the long-term safety of a new gene therapy, JNJ-81201887, for Geographic Atrophy (GA), a severe eye condition. It involves people who previously took part in earlier studies of this treatment, to see how they are doing over several years.